Status:
COMPLETED
Pharmacokinetics of Insulin Detemir in Subjects With Type 2 Diabetes
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This trial is conducted in the United States of America (USA). The aim of this trial is to evaluate the the dose-response of insulin detemir and insulin NPH in subjects with type 2 diabetes of various...
Eligibility Criteria
Inclusion
- Type 2 diabetes
- Insulin treatment with any insulin preparation/regimen for at least three months with or without combination with below or equal to 2 oral antidiabetic agents (OADs)
- Duration of diabetes at least 12 months
- Body Mass Index (BMI) below 33 kg/m\^2
- HbA1c maximum 10 % based on analysis from the central laboratory
Exclusion
- Current treatment with insulin above 1.2 U/kg/day
- Current treatment with drugs known to interfere with glucose metabolism other than OADs such as systemic corticosteroids, non-selective beta-blockers, and monoamino oxidase (MAO) inhibitors
- Blood donation of more than 500 mL within the last three months
Key Trial Info
Start Date :
February 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2004
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT01497600
Start Date
February 1 2004
End Date
August 1 2004
Last Update
January 27 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Chula Vista, California, United States, 91911